Christopher Mancuso has experience in research as an undergraduate and graduate student at Johns Hopkins University. His interests conducting benchwork and working on clinical studies have been in the fields of neurosurgery and dermatology. Currently, he is a third year medical student at Nova Southeastern University College of Osteopathic Medicine and hopes to pursue a career as a dermatologist and Mohs surgeon.
Keloid scarring is a chronic disfiguring condition that is characterized as overproduction of collagen caused by excessive fibroblast proliferation in response to dermal injury [1, 2]. Diagnosis of keloids is based on the clinical presentation and history. The treatment options include one or a combination of the following: intralesional injections of corticosteroids or 5-fluorouracil, topical Imiquimod or silicone gel sheets, pressure therapy, cryotherapy, surgical excision, radiation therapy, and laser therapy . It has been proposed that a combination of intralesional corticosteroid injections with surgical excision be considered as a first-line therapy for earlobe keloids . While there is a large body of research on keloids and the treatments have been well established, the recurrence rates remain high and variable and there are currently no available guidelines or algorithms for the number of injections of corticosteroids that should precede surgical excision. The goal of this case report is to demonstrate the use of xenografts in the reconstruction of keloid excisions on the ear.
Dr. Kwan-Kyu Park, M.D., Ph.D., now is a professor of pathology, a chief of the pathology laboratory in college of medicine, Catholic University of Daegu, based in Daegu, Republic of Korea. Prof. Park has published over 300 papers about various inflammatory disease and pathology. He is an expert in kidney and liver pathology and his main research interest is inflammatory diseases including dermatitis. He is also interested in therapeutic effects of bee venom and its component on various diseases. The papers he published about bee venom are over 30. Further, he has been studied about gene therapy using oligodeoxynucleotide decoy and siRNA. Currently, Dr. Park Kwan-Kyu leads 8 members of the pathology laboratory, and works as a specialist for Daegu Catholic University Medical Center.
Atopic dermatitis (AD) is a multifactorial skin disease, with complex interactions of innate and adaptive immune responses based on a genetic, pharmacological and psychological predisposition. Purified bee venom (BV) and its major component melittin (Mel) has been widely used as a traditional medicine for various diseases. It has multiple effects including antibacterial, antiviral, and anti-inflammatory activities in various cell types. However, the precise mechanism of BV and Mel in ameliorating the AD is not fully understood. This study investigated the pharmacological effects of BV and Mel on AD symptoms by using tumor necrosis factor (TNF)-α-/interferon (IFN)-γ-activated human keratinocyte. The human keratinocyte HaCaT cells were pretreated with BV (1, 10 and 100 ng/ml), and Mel (0.1, 0.5 and 1 µg/ml) for 30 min and then stimulated with recombinant human TNF-α/IFN-γ (10 ng/ml) for 9 h. In order to determine whether BV and Mel inhibit thymus-and activation-regulated chemokine (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22), this study analyzed these chemokines with real-time PCR in mRNA HaCaT cells. BV and Mel inhibited the mRNA expression of TARC/CCL17 and MDC/CCL2 in TNF-α-/IFN-γ-stimulated HaCaT cells. In addition, BV and Mel treatment suppressed the expression of pro-inflammatory cytokines such as IL-1 β, IL-6, and IFN-γ in protein level of TNF-α-/IFN-γ-stimulated HaCaT cells. And also, BV and Mel effectively inhibited NF-κB signaling pathway and JAK2-mediated distal signaling phospho-STAT1 and phospho-STAT3 in TNF-α/IFN-γ-stimulated HaCaT cells. In conclusion, this study provides novel insights into the pharmacological actions of BV and Mel as a potential agent for use in the treatment of AD-like skin lesions.